Molecule
Copper oxodotreotide cu-64 is a radioactive diagnostic agent indicated with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. It is available as injection for intravenous use. MedsAcross supplies Copper oxodotreotide cu-64 for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. Detectnet is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.
Source: US FDA prescribing information
Copper Cu 64 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSTR2). It binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress SSTR2 receptors. Copper Cu 64 is a positron (β + ) emitting radionuclide with an emission yield that allows positron emission tomography (PET) imaging.
Source: US FDA prescribing information
Recommended dose is 148 MBq (4 mCi) administered as an intravenous bolus injection. Begin acquiring images 45 to 90 minutes after drug administration. See full prescribing information for additional preparation, administration, imaging and dosimetry information.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Radiation Risk: Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration. Hypersensitivity Reactions: Most reported reactions were rash and pruritus and reversible either spontaneously or with routine symptomatic management. Risk for Image Misinterpretation: Uptake of Detectnet can be seen in a variety of tumor types other than NETs, in other pathologic conditions, and as a normal physiologic variant (e.g., uncinate process of the pancreas).
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity reactions Reported adverse reactions include nausea, vomiting, and flushing.
Source: US FDA prescribing information
Somatostatin Analogs: Somatostatin analogs competitively bind to the same somatostatin receptors as copper Cu 64 dotatate and may affect imaging. Image patients just prior to dosing with somatostatin analogs. For patients on long-acting somatostatin analogs, a wash-out period of 28 days is recommended prior to imaging. For patients on short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging.
Source: US FDA prescribing information
Store Detectnet at controlled room temperature 20 ° C to 25 ° C (68 ° F to 77 ° F). Store Detectnet in an upright position within the lead shielding to protect handlers from exposure to radiation. Store and dispose of Detectnet in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Copper oxodotreotide cu-64, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Detectnet 1 mCi/mL injectionIntravenous | Curium | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | Not recorded | — |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Copper oxodotreotide cu-64 and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Copper oxodotreotide cu-64, including Detectnet.
No listed presentation of Copper oxodotreotide cu-64 is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.